CXCL5 and lung carcinoma: For example, in a mouse lung cancer model, CXCL5 antibodies synergistically enhanced the therapeutic effect of the tyrosine kinase inhibitor gefitinib through activating the AKT/NF‐κB and ERK/RSK1/2 signaling pathways.298